How to make the personalized antitumor vaccine and how it works (Image by NCNST)
Thanks to the rapid development of nanotechnology, a research team led by Profs. NIE Guangjun, WU Yan and ZHAO Yuliang from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences (CAS) recently designed personalized tumor vaccines based on bacterial cytoplasmic membranes and cell membranes from resected tumor tissue. This work was published in Science Translational Medicine.
Cancer vaccines are an effective anti-tumor therapeutic option that utilize tumor antigens to stimulate patients’ immune response and specifically kill tumor cells. Postoperative recurrence and metastasis after surgery can thus be effectively inhibited by the activated immune system. Therefore, it is important for scientists and clinicians to find the best way to train the patient’s own immune system to find these tumor cells.
Using surgically removed tumor tissue is a very attractive way for making a patient’s own anti-cancer vaccine, since such a vaccine would contain the personalized antigen spectrum of the tumor cells. However, since there is only a small difference between the tumor antigens and the body’s own proteins, the antigens may be recognized as “self” by the patients’ own immune system. As a result, tumor antigens are more likely to induce antigen-specific tolerance than antitumor immunity.
Cancer immunotherapy faces the challenge of how to educate the immune system to distinguish tumor components as “non-self.” Most of the time, bacteria are easily identified as invaders and cleared out by the immune system. Some researchers have tried to use bacteria or their components as adjuvants to enhance immunogenicity. However, nonspecific stimulation of the immune system by bacteria or their components may elicit severe side effects.
For example, lipopolysaccharides—large molecules found in the cell walls of Gram negative bacteria—may cause lethal cytokine storms. Therefore, it is critically important to develop powerful anti-cancer vaccines that educate patients’ own immune systems to find cancer cells but do not induce side effects.
In this work, the research team designed a hybrid membrane nanovaccine for personalized immunotherapy to overcome the challenges described above. The tumor membrane antigens and bacterial inner membrane were fused and displayed on the surface of polymer nanoparticles. Introducing cytoplasmic membranes of E. coli, one of the most common bacteria in the human gut, into the hybrid membrane nanoparticle vaccines induced dendritic cell (DC) maturation, thus activating splenic T cells.
The hybrid membrane-coated nanoparticles represent a novel vaccine strategy that simultaneously delivers antigens and adjuvants to DCs to provoke robust innate and tumor-specific adaptive immune responses. In mouse tumor models, this strategy prevented tumor recurrence, with prolonged tumor-bearing animal survival and tumor-specific, long-term protection against tumor rechallenge.
In conclusion, this hybrid membrane-based antitumor immunity platform with intrinsic adjuvant properties offers a new opportunity for the development of individualized cancer vaccines for a broad range of solid tumors.
Original Article: Personalized Tumor Vaccines May Solve Tumor Recurrence and Metastasis Challenges
More from: National Center for Nanoscience and Technology
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Personalized tumor vaccines
- How mRNA vaccines could be personalized cancer cures
An expanding pipeline of vaccines is giving patients new hope against some of the deadliest cancers, by training the body's immune system to attack malignancies. Why it matters: This personalized ...
- Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogs
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.
- New mRNA vaccine shows promise in fighting brain tumors
F ORT LAUDERDALE, Fla. ( NewsNation) — In a first-ever human clinical trial, researchers at the University of Florida developed an mRNA vaccine that reprograms the immune system to fight the most ...
- mRNA vaccine tackles deadly brain cancer in human trial
Glioblastoma is one of the most deadly cancers, with few treatment options available. Now, a small human clinical trial has demonstrated an mRNA vaccine that quickly rallies the immune system to fight ...
- Personalized mRNA vaccines: A new approach in melanoma treatment
A personalized mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.
Go deeper with Google Headlines on:
Personalized tumor vaccines
[google_news title=”” keyword=”Personalized tumor vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Tumor vaccines
- Fact Check: No evidence of mRNA cancer ‘explosion’ in Japan, no national emergency declared
Japan has not declared a national emergency over a purported explosion of cancer cases, a health ministry official told Reuters, adding that mRNA vaccines do not cause cancer.
- New mRNA cancer vaccine helps immune system fight deadly brain tumors
Researchers from the University of Florida have developed a new mRNA cancer vaccine to retrain the body's immune system to attack and potentially treat glioblastoma, a deadly form of brain cancer.
- How mRNA vaccines could be personalized cancer cures
An expanding pipeline of vaccines is giving patients new hope against some of the deadliest cancers, by training the body's immune system to attack malignancies. Why it matters: This personalized ...
- Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogs
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.
- New mRNA vaccine shows promise in fighting brain tumors
F ORT LAUDERDALE, Fla. ( NewsNation) — In a first-ever human clinical trial, researchers at the University of Florida developed an mRNA vaccine that reprograms the immune system to fight the most ...
Go deeper with Google Headlines on:
Tumor vaccines
[google_news title=”” keyword=”tumor vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]